Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111682 | 0.84 | HTR7 (0.56) | HTR7SIGMAR1HRH3KDM4EALDH1A1 | |
| SCHEMBL7097670 | 0.83 | LMNA (0.49) | HTR7SIGMAR1OPRM1OPRK1 | |
| SCHEMBL1111765 | 0.82 | HTR7 (0.44) | HTR7HRH3OPRM1OPRK1 | |
| SCHEMBL11370179 | 0.81 | CXCR4 (0.48) | HTR7SIGMAR1CYP2A13HRH3ALDH1A1 | |
| SCHEMBL1111800 | 0.81 | HTR7 (0.60) | HTR7HRH3 | |
| SCHEMBL1111683 | 0.81 | HTR7 (0.64) | HTR7HRH3 | |
| SCHEMBL1111899 | 0.78 | ALDH1A1 (0.49) | HTR7PTAFRKDM4EALDH1A1RAB9A | |
| SCHEMBL1111700 | 0.78 | HTR7 (0.50) | HTR7HRH3ALDH1A1 | |
| SCHEMBL1111920 | 0.78 | SIGMAR1 (0.50) | HTR7SIGMAR1PTAFRCYP2A13KDM4E | |
| SCHEMBL1578951 | 0.77 | SIGMAR1 (0.66) | SIGMAR1CYP2A13KDM4EALDH1A1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | HTR7 2134/4885SIGMAR1 2606/4885PTAFR 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.